Skip to main content
Search

The path towards a cure for chronic hepatitis B

Published on January 30, 2022   9 min

A selection of talks on Pharmaceutical Sciences

Please wait while the transcript is being prepared...
0:00
Hello, I'm Professor Fabien Zoulim from Lyon University working at the Hepatology Department of the Hospices Civils de Lyon and at INSERM U1052. Today I will be giving a presentation on the path towards a cure for chronic hepatitis B.
0:20
Chronic HBV infection remains a major public health problem with more than 250 million chronic carriers worldwide. The elimination of HBV infection will require a concerted action, with better vaccine coverage among the population, and improved access to antiviral treatment to treat all chronic carriers. Currently, the antiviral treatments are mainly suppressive, they are not curative, so the field of HBV has made a lot of research to better understand the mechanism involved in the molecular pathogenesis and the viral persistence with experimental studies that were performed in cultured hepatocytes, in humanized mouse studies, and in patients with translational studies. All these new insights have allowed us to identify novel targets, and have allowed us to discover novel antiviral drugs. These studies have also allowed us to identify novel biomarkers and the current clinical studies are evaluating the novel antiviral drugs and immunotherapeutics with the help of the novel biomarkers to investigate whether the new strategies will improve the cure rate of infection and will improve the prevention of hepatocellular carcinoma. As I've said, the current anti-viral treatments are mainly suppressive.

Quiz available with full talk access. Request Free Trial or Login.

Show
Hide

The path towards a cure for chronic hepatitis B

Embed in course/own notes